For example, the efficacy of CD133-targeting chimeric antigen receptor T-cells has been investigated in a Phase I clinical trial in patients with hepatocellular carcinoma, pancreatic carcinoma, and colorectal carcinoma. The gene discussed is PROM1; the disease is exocrine pancreatic carcinoma.